These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 28041920)

  • 1. Secondary cvd prevention-Lipid modification strategies: A critical analysis.
    Ghosal S; Sinha B
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S187-S193. PubMed ID: 28041920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
    Lardizabal JA; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids).
    Elshazly MB; Martin SS; Blaha MJ; Joshi PH; Toth PP; McEvoy JW; Al-Hijji MA; Kulkarni KR; Kwiterovich PO; Blumenthal RS; Jones SR
    J Am Coll Cardiol; 2013 Nov; 62(21):1960-1965. PubMed ID: 23973689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin-prescribing trends for primary and secondary prevention of cardiovascular disease.
    Brown F; Singer A; Katz A; Konrad G
    Can Fam Physician; 2017 Nov; 63(11):e495-e503. PubMed ID: 29138175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study.
    Lozano JV; Pallarés V; Cea-Calvo L; Llisterri JL; Fernández-Pérez C; Martí-Canales JC; Aznar J; Gil-Guillén V; Redón J;
    Curr Med Res Opin; 2008 Mar; 24(3):659-70. PubMed ID: 18218194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults.
    Takeuchi T; Nemoto K; Takahashi O; Urayama KY; Deshpande GA; Izumo H
    J Clin Lipidol; 2014; 8(5):501-9. PubMed ID: 25234563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.
    Pirro M; Del Giorno R; Lupattelli G; Mannarino MR; Roscini AR; Covelli D; Schillaci G; Pasqualini L; Bagaglia F; Siepi D; Mannarino E
    Eur J Intern Med; 2011 Aug; 22(4):412-7. PubMed ID: 21767761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.
    Rollefstad S; Ikdahl E; Hisdal J; Kvien TK; Pedersen TR; Holme I; Semb AG
    Ann Rheum Dis; 2015 Aug; 74(8):1544-50. PubMed ID: 24699940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low high-density lipoprotein cholesterol as the possible risk factor for stroke.
    Demarin V; Lisak M; Morović S; Cengić T
    Acta Clin Croat; 2010 Dec; 49(4):429-39. PubMed ID: 21830454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C
    Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lowering of lipids: a true prevention?--a justified therapy?--a true controversy?].
    Stähelin HB
    Schweiz Med Wochenschr; 1980 Mar; 110(13):478-84. PubMed ID: 7375898
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.